Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial

IMPORTANCE: Papillary renal cell carcinoma (PRCC) is the most common type of non–clear cell RCC. Because some cases of PRCC are MET-driven, MET inhibition could be a targeted treatment approach. In previous studies, savolitinib (AZD6094, HMPL-504, volitinib), a highly selective MET-tyrosine kinase i...

Descripción completa

Detalles Bibliográficos
Autores principales: Choueiri, Toni K., Heng, Daniel Y. C., Lee, Jae Lyun, Cancel, Mathilde, Verheijen, Remy B., Mellemgaard, Anders, Ottesen, Lone H., Frigault, Melanie M., L’Hernault, Anne, Szijgyarto, Zsolt, Signoretti, Sabina, Albiges, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260692/
https://www.ncbi.nlm.nih.gov/pubmed/32469384
http://dx.doi.org/10.1001/jamaoncol.2020.2218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260692/
https://www.ncbi.nlm.nih.gov/pubmed/32469384
http://dx.doi.org/10.1001/jamaoncol.2020.2218

Ejemplares similares